More on AB
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $36.16 |
|
|||
| Open | $36.29 | ||||
| 52 Wk High | $26.24 | ||||
| 52 Wk Low | $16.11 | ||||
| Day High | $36.47 | ||||
| Day Low | $35.75 | ||||
| P/E | 21.15 | ||||
| EPS | $1.70 | ||||
| Volume | 408,048 | ||||
- AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
- Bernstein Private Wealth Management Study Reveals Ultra-Wealthy Families' Focus on Internal Resilience amid Global and Economic Uncertainty
- Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Jun 10
- AllianceBernstein AUM rises 2% to $899 billion in May 2026
- AB Announces May 31, 2026 Assets Under Management
- AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
- AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share
- AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
- Form 4 ALLIANCEBERNSTEIN HOLDIN For: May 20 Filed by: Holley Bruce M
- Form 4 ALLIANCEBERNSTEIN HOLDIN For: May 20 Filed by: Stonehill Charles G.T.
Entities mentioned with AB
- Earnings | View Related Stories »
- Sanford C. Bernstein | View Related Stories »
- Definitive Agreement | View Related Stories »
- Barclays | View Related Stories »
- Dividend | View Related Stories »
- FDA | View Related Stories »
- Citi | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
